Drugs / MEDI0618
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04198558 | Nov 2019 → Feb 2022 | chronic pain syndrome | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06602479 | Oct 2024 → Dec 2026 expected | migraine disorder | AbbVie | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05714254 Comparator | Dec 2022 → Dec 2023 | chronic pain syndrome | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI0618 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06602479 ↗ |
| Action | Inhibit | “Protease-Activated Receptor 2 Antagonist” NCT05714254 ↗ |
| Modality | Monoclonal antibody | “MEDI0618 A novel human immunoglobulin antibody” NCT04198558 ↗ |
| Route | Intravenous | “by intravenous administration” NCT04198558 ↗ |